Sökning: onr:"swepub:oai:lup.lub.lu.se:468a17c1-1078-4f42-8aaf-ad8face328b1" > Expression of HGF, ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08350naa a2200589 4500 | |
001 | oai:lup.lub.lu.se:468a17c1-1078-4f42-8aaf-ad8face328b1 | |
003 | SwePub | |
008 | 201028s2020 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:liu-170541 | |
009 | oai:gup.ub.gu.se/296564 | |
024 | 7 | a https://lup.lub.lu.se/record/468a17c1-1078-4f42-8aaf-ad8face328b12 URI |
024 | 7 | a https://doi.org/10.1002/1878-0261.128032 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1705412 URI |
024 | 7 | a https://gup.ub.gu.se/publication/2965642 URI |
040 | a (SwePub)lud (SwePub)liud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Sjöström, Martinu Lund University,Lunds universitet,Bröstcancer Proteogenomik,Forskargrupper vid Lunds universitet,Individuell Bröstcancerbehandling,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast cancer Proteogenomics,Lund University Research Groups,Personalized Breast Cancer Treatment,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Sweden4 aut0 (Swepub:lu)med-msm |
245 | 1 0 | a Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial |
264 | c 2020-09-28 | |
264 | 1 | b Wiley,c 2020 |
300 | a 14 s. | |
500 | a Funding Agencies|Governmental Funding of Research within the National Health Service (ALF-agreement); Swedish Cancer SocietySwedish Cancer Society; Anna and Edwin Berger Foundation; Swedish Breast Cancer Association; Mrs Berta Kamprad Foundation; Faculty of Medicine at Lund University; Lund University Research Foundation; Skane County Research Foundation (FOU); Marcus and Marianne Wallenberg Foundation | |
520 | a Experimental studies suggest that hepatocyte growth factor (HGF) and its transmembrane tyrosine kinase receptor, Met, in part also relying on Akt kinase activity, mediate radioresistance. We investigated the importance of these biomarkers for the risk of ipsilateral breast tumour recurrence (IBTR) after adjuvant radiotherapy (RT) in primary breast cancer. HGF, phosphorylated Met (pMet) and phosphorylated Akt (pAkt) were evaluated immunohistochemically on tissue microarrays from 1004 patients in the SweBCG91-RT trial, which randomly assigned patients to breast-conserving therapy, with or without adjuvant RT. HGF was evaluated in the stroma (HGFstr); pMet in the membrane (pMetmem); HGF, pMet and pAkt in the cytoplasm (HGFcyt, pMetcyt, pAktcyt); and pAkt in the nucleus (pAktnuc). The prognostic and treatment predictive effects were evaluated to primary endpoint IBTR as first event during the first 5 years. Patients with tumours expressing low levels of HGFcyt and pMetcyt and high levels of pAktnuc derived a larger benefit from RT [hazard ratio (HR): 0.11 (0.037–0.30), 0.066 (0.016–0.28) and 0.094 (0.028–0.31), respectively] compared to patients with high expression of HGFcyt and pMetcyt, and low pAktnuc [HR: 0.36 (0.19–0.67), 0.35 (0.20–0.64) and 0.47 (0.32–0.71), respectively; interaction analyses: P = 0.052, 0.035 and 0.013, respectively]. These differences remained in multivariable analysis when adjusting for patient age, tumour size, histological grade, St Gallen subtype and systemic treatment (interaction analysis, P-values: 0.085, 0.027, and 0.023, respectively). This study suggests that patients with immunohistochemically low HGFcyt, low pMetcyt and high pAktnuc may derive an increased benefit from RT after breast-conserving surgery concerning the risk of developing IBTR. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Akt | |
653 | a breast cancer | |
653 | a HGF | |
653 | a Met | |
653 | a radiotherapy | |
653 | a treatment prediction | |
653 | a Akt; breast cancer; HGF; Met; radiotherapy; treatment prediction | |
700 | 1 | a Veenstra, Cynthiau Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US4 aut0 (Swepub:liu)cynve22 |
700 | 1 | a Holmberg, Erik,d 1951u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xholer |
700 | 1 | a Karlsson, Per,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xkperd |
700 | 1 | a Killander, Fredrikau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-fki |
700 | 1 | a Malmström, Peru Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-pma |
700 | 1 | a Niméus, Emmau Lund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Bröstcancer Proteogenomik,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Biomarkörer och Epi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast Cancer Surgery,Lund University Research Groups,Breast cancer Proteogenomics,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Biomarkers and epidemiology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-ens |
700 | 1 | a Fernö, Mårtenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Institutionen för kliniska vetenskaper, Lund,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Breast Cancer Treatment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Department of Clinical Sciences, Lund,Lund Univ, Sweden4 aut0 (Swepub:lu)onk-mfe |
700 | 1 | a Stål, Olleu Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US4 aut0 (Swepub:liu)ollst87 |
710 | 2 | a Bröstcancer Proteogenomikb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Molecular Oncologyd : Wileyg 14:11, s. 2713-2726q 14:11<2713-2726x 1574-7891x 1878-0261 |
856 | 4 | u http://dx.doi.org/10.1002/1878-0261.12803x freey FULLTEXT |
856 | 4 | u https://febs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.12803 |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1476966/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://lup.lub.lu.se/record/468a17c1-1078-4f42-8aaf-ad8face328b1 |
856 | 4 8 | u https://doi.org/10.1002/1878-0261.12803 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170541 |
856 | 4 8 | u https://gup.ub.gu.se/publication/296564 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy